Why Iovance Biotherapeutics Stock Is Crashing Today

In This Article: Key Points - Iovance's Q1 revenue was sharply lower than expected. - The company blamed the miss on lower production capacity due to annual maintenance at its cell therapy facility. - However, Iovance's full-year revenue guidance cut hints at a deeper problem. Shares of Iovance…